Preliminary Program and Speakers Announced for 2nd International Symposium on MR-guided Focused Ultrasound
Excitement is building for the 2nd International Symposium on MR-guided Focused Ultrasound, which has just announced that its roster of speakers, moderators and discussion leaders will include many internationally-known thought leaders, clinicians and researchers. Please see below for details.
Late last week, Israeli blogger Mouli Cohen wrote about the use of MR-guided focused ultrasound to treat stroke (see his blog here).
Cohen wrote about the work being done by Thilo Hoelscher M.D. at the University of California at San Diego. Dr. Hoelscher is conducting FUS Foundation-funded research using InSightec's high-intensity focused ultrasound (HIFU) system, the ExAblate.
Zürich Transcranial FUS Results Presented at Annual Meeting
Professor Daniel Jeanmonod faced a packed meeting room at the Philadelphia convention Center on May 3 when he presented his much-anticipated results treating 12 patients in Zürich using transcranial MR-guided focused ultrasound (TcFUS). Many neurosurgeons in the audience at the Stereotactic and Functional Neurosurgery Session of the 2010 annual meeting of the American Association of Neurological Surgeons were there mainly for his presentation.
He reported on 18 ablative lesions performed in 12 patients using transcranial central lateral thalamotomy with the Exablate 4000 (Insightec Ltd, Haifa). All patients suffered from chronic therapy-resistant neuropathic pain, including some who had failed prior radiofrequency lesioning. Real-time MR image monitoring (thermometry) was performed in awake patients, allowing for on-line control of targeting parameters, precision and safety.
His work confirmed the high level of precision in lesion placement (< 1.0 mm) that had been previously reported (Martin E. et al., Annals of Neurology 66(6):858-861, 2009). Skull heating was minimal.
Peri-lesional edema appeared on MRI within 48 hours, but was resolved at the time of the 1-month MRI.
The Foundation congratulates Toronto-based Profound Medical, Inc., winner of the prestigious, 2010 Ontario Premier’s Catalyst Award for “Start-up Company with the Best Innovation.” The Ontario government will also invest C$ 200,000 in further developing the company’s investigational MR-guided focused ultrasound device for treating prostate cancer.
The company is in the midst of securing financing to accelerate clinical trials in North America, Canada and the European Union.